Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
3347 Stock Chart & Stats
HK$54.00
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$54.00
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$22.30 - HK$60.60
Previous CloseN/A
Volume678.40K
Average Volume (3M)2.64M
Market Cap
HK$47.82B
Enterprise ValueHK$40.50B
Total Cash (Recent Filing)HK$1.84B
Total Debt (Recent Filing)HK$1.47B
Price to Earnings (P/E)37.1
Beta1.81
Next Earnings
Apr 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.8%
Share Statistics
EPS (TTM)-0.17
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$55.78Price Target Upside3.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.41
Revenue Forecast (FY)HK$8.72B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a conservatively financed balance sheet give Tigermed flexibility to absorb payment delays or cycle downturns, bid for larger or longer-duration trials, and fund strategic investments without heavy external financing. This cushion supports operational stability and credit optionality.
Comprehensive CRO Service OfferingTigermed's multi-service model—clinical operations, data/biostatistics, regulatory affairs and ancillary trial support—creates cross-sell opportunities and client stickiness. Long-duration, multi-service contracts foster recurring revenue and make the business less dependent on any single service line or short-term project wins.
Positive Cash GenerationDespite pressure, Tigermed generates meaningful operating cash flow and positive free cash flow that covered a large share of net income (~81% in 2025). Persistent cash generation enables reinvestment in delivery capacity, supports working capital needs, and reduces reliance on external funding for near-term strategic moves.
Bears Say
Declining Free Cash Flow TrendA multi-year decline in free cash flow erodes internal funding for business development and capacity expansion. Lower FCF reduces flexibility for strategic investments or buffering margin shocks, forcing greater sensitivity to working capital swings and potentially increasing dependence on external financing if the trend continues.
Volatile And Compressed ProfitabilitySharp margin swings indicate pricing pressure, adverse mix shifts or cost volatility that undermine earnings predictability. Even with partial recovery, margins remain below prior peaks, weakening return on capital and making future cash flow and reinvestment planning less reliable for long-term growth initiatives.
Roughly Flat Revenue GrowthSubdued top-line growth limits the company's ability to leverage fixed costs and achieve stronger operating leverage. Without stronger revenue expansion, Tigermed must rely on margin improvements to drive earnings growth, leaving performance vulnerable if competition or pricing pressures persist.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$22.30 and its highest was HK$60.60 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$47.82B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Apr 29, 2026 which is in 23 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported -HK$0.175 earnings per share for the quarter, missing the consensus estimate of -HK$0.079 by -HK$0.096.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.325 which represents an annual dividend yield of 0.8%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of -HK$0.175 in its last earnings report, missing expectations of -HK$0.079. Following the earnings report the stock price went down -1.304%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$55.78 (3.29% Upside)
HK$55.78 (3.29% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
2.95%
Trailing 12-Months
Asset Growth
-8.95%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
3347 Stock 12 Month Forecast
Average Price Target
HK$55.78
▲(3.29% Upside)
Technical Analysis
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
Giant Biogene Holding Co. Ltd.
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---